NUTX
Nutex HealthAAI scenario view
RankAlpha Sentiment CodexAI sentiment snapshot
AI commentary
Coverage is concentrated in earnings summaries and valuation syndication rather than a broad, independently confirmed analyst-revision cycle. Secondary coverage cited a strong post-Q1 price reaction, but social context, options data, short interest, and employee sentiment were not provided. Primary-source quality is strong, but forward visibility remains moderate; this is a monitoring-style setup rather than a high-conviction momentum call.
Evidence flagged
No evidence quality warning is currently attached to this memo.
AI events
The April 30, 2026 filing reported Q1 revenue of $216.5 million, net income of $46.8 million, diluted EPS of $6.52, operating cash flow of $75.5 million, same-hospital revenue growth of 0.2%, same-hospital visits up 0.6%, and an over-85% win rate on decided IDR determinations. This supports the current earnings base but leaves durability tied to reimbursement capture [#SEC-8K-2026-04-30].
The Q1 2026 Form 10-Q reported 200,444 shares repurchased or retired during the quarter across existing and new programs. The effect is supportive only if operating cash generation and reimbursement collections remain durable [#SEC-10Q-2026-04-30].
Management expects to open three new hospital facilities by the end of 2026, while the Q1 update also described selective self-development through the real-estate division. Successful openings could broaden growth beyond IDR economics; delays would weaken forward visibility [#10-K-2026-03-05] [#8-K-2026-04-30].
Recommendation
No formal recommendation provided.

